Clinical importance of microtubule-associated protein 1 light chain 3 and mammalian target of rapamycin expression in oral leukoplakia and oral squamous cell carcinoma.
- Author:
Xiao-Lin DONG
1
;
Zhi-Wen LIU
1
Author Information
- Publication Type:Journal Article
- Keywords: leukoplakia; mammalian target of rapamycin; microtubule-associated protein 1 light chain 3
- MeSH: Biomarkers, Tumor; metabolism; Carcinoma, Squamous Cell; diagnosis; metabolism; Humans; Leukoplakia, Oral; diagnosis; metabolism; Microtubule-Associated Proteins; metabolism; Mouth Mucosa; Mouth Neoplasms; diagnosis; metabolism; TOR Serine-Threonine Kinases; metabolism
- From: West China Journal of Stomatology 2018;36(6):613-618
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:This study aimed to investigate the expression and relationship of microtubule-associated protein 1 light chain 3 (LC3) and mammalian target of rapamycin (mTOR) in normal oral mucosa, oral leukoplakia (OLK), and oral squamous cell carcinoma (OSCC). This work also analyzed the relationship between expression levels and clinical factors. This study evaluated the clinical value of LC3B and mTOR as indices to determine the carcinogenic potential of OLK.
METHODS:Immunohistochemistry was used to detect the expression of LC3B and mTOR in 20 cases of normal oral mucosa, 120 cases of OLK, and 30 cases of OSCC. The clinical data of 120 patients with OLK were analyzed. The relationships between expression levels and clinical factors were investigated.
RESULTS:In normal oral mucosa, OLK and OSCC, the positive rates of LC3B expression were 85.0%, 65.8% and 33.3% (P<0.05), whereas the positive rates of mTOR expression were 20.0%, 48.3% and 76.7% (P<0.05). The expression levels of LC3B and mTOR were correlated and related to clinical typing of OLK (P<0.05).
CONCLUSIONS:LC3B and mTOR can be used as molecular biomarkers for early detection of OLK.
